Tirzepatide Heartburn: How Common, How Long It Lasts
Yes. Heartburn and indigestion is listed in 2 of 2 tirzepatide labels. The highest rate in each label runs from 8% on Mounjaro to 10% on Zepbound. Placebo in the Zepbound trials: 4%. Smaller, slower meals help most.
- Labels that list it
- 2 of 2
- Highest rate
- 10% Zepbound
- Lowest rate
- 8% Mounjaro
Zepbound facts at a glance
Its half-life is 5 to 6 days. At 5.5 d, half remains, and five half-lives (27.5 d) leave about 3%.
Across 72 weeks, SURMOUNT-1 reported 20.9% of body weight, compared with 3.1% on placebo.
US dollar monthly prices consist of the list price and self-pay offers. Each was taken from the maker's price page.
Sources: FDA label (DailyMed), Eli Lilly 1 2, cnbc.com.
Rates on tirzepatide and placebo
Tirzepatide heartburn appears here for each dose group in the label trials. Within each trial, the placebo group provides the comparison.
| Medicine and dose | Heartburn and indigestion | Placebo | More than placebo | People in the trials |
|---|---|---|---|---|
| Mounjaro 5 mg | 8% | 3% | +5 points | Adults with type 2 diabetes (label term: dyspepsia) |
| Mounjaro 10 mg | 8% | 3% | +5 points | Adults with type 2 diabetes (label term: dyspepsia) |
| Mounjaro 15 mg | 5% | 3% | +2 points | Adults with type 2 diabetes (label term: dyspepsia) |
| Zepbound 5 mg | 9% | 4% | +5 points | Weight management: adults with obesity or overweight |
| Zepbound 10 mg | 9% | 4% | +5 points | Weight management: adults with obesity or overweight |
| Zepbound 15 mg | 10% | 4% | +6 points | Weight management: adults with obesity or overweight |
| Zepbound 5 mg | 4% | 2% | +2 points | The label term is gastroesophageal reflux disease; this group is adults with obesity or overweight (weight management) |
| Zepbound 10 mg | 4% | 2% | +2 points | The label term is gastroesophageal reflux disease; this group is adults with obesity or overweight (weight management) |
| Zepbound 15 mg | 5% | 2% | +3 points | The label term is gastroesophageal reflux disease; this group is adults with obesity or overweight (weight management) |
Labels used: Zepbound label (DailyMed), Mounjaro label (DailyMed).
Tirzepatide Heartburn compared with other GLP-1s
The trials covered by each label involved different groups of people. Treat it as a rough guide.
Pill forms are also included in the table: Foundayo.
| Medicine | Highest rate in the label | Dose group | Placebo | People in the trials |
|---|---|---|---|---|
 Foundayo | 16% | 9 mg | 4% | Adults with obesity or overweight (weight management) |
 Zepbound | 10% | 15 mg | 4% | Adults with obesity or overweight (weight management) |
 Saxenda | 9.6% | all doses | 2.7% | Adults with obesity or overweight (weight management) |
 Wegovy | 9% | 2.4 mg | 3% | Adults with obesity or overweight (weight management) |
 Mounjaro | 8% | 5 mg | 3% | Adults with type 2 diabetes |
 Victoza | 7% | 1.8 mg | 1% | Adults with type 2 diabetes |
| Byetta | 6% | all doses | 3% | Adults with type 2 diabetes |
 Trulicity | 5.8% | 1.5 mg | 2.3% | Adults with type 2 diabetes |
 Ozempic | Listed, no rate given | – | – | – |
 Rybelsus | Listed, no rate given | – | – | – |
Sources: Wegovy label (DailyMed), Mounjaro label (DailyMed), Zepbound label (DailyMed), Foundayo label (DailyMed), Trulicity label (DailyMed), Saxenda label (DailyMed), Victoza label (DailyMed), Byetta label (DailyMed).
Source: FDA label (DailyMed).
Why it happens on tirzepatide
These medicines slow down how quickly the stomach empties. Food stays in your stomach longer, so heartburn and indigestion may follow, especially after a large or fatty meal.
The health.clevelandclinic.org site is the source.
What the Mounjaro label says
The label uses these terms for heartburn and indigestion:
“15 mg): eructation (0.4%, 3.0%, 2.5%, 3.3%), flatulence (0%, 1.3%, 2.5%, 2.9%), gastroesophageal reflux disease (0.4%, 1.7%, 2.5%, 1.7%), abdominal distension (0.4%, 0.4%, 2.9%, 0.8%).”
Source: FDA label (DailyMed).
What helps, step by step
- For now, avoid spicy and fatty foods.
- Stay upright after meals instead of lying down.
- Eat smaller meals and stop when you feel full. With these medicines, the stomach empties more slowly.
- Eat slowly. Some time passes before your brain senses that you are full.
- Reduce fatty, greasy and sugary foods, because they often cause symptoms.
- If the symptoms do not ease, tell your prescriber. Your prescriber may suggest another GLP-1 or slow the dose increases.
Before taking anything from the drugstore, check it using the GLP-1 interactions checker.
The health.clevelandclinic.org site is the source.